Charts

News

09 Apr, 2024
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (
27 Mar, 2024
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida. NCCN 2024 Annual Conference – Orlando World Center Marriott
25 Mar, 2024
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stag
11 Mar, 2024
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation
07 Mar, 2024
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations were $-0.78. PSTV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen. Welcome […]
Plus Therapeutics ( NASDAQ:PSTV ) Full Year 2023 Results Key Financial Results Revenue: US$4.91m (up by US$4.69m from...
06 Mar, 2024
Q4 2023 Plus Therapeutics Inc Earnings Call
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. The post PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.
05 Mar, 2024
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
21:35
FinancialContent
Plus Therapeutics (NASDAQ:PSTV) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:05 PM. Here's what investors need to ...
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites Current financial forecast for sufficient runway to fund operations into 2H 2025 Management to Host Conference Call March 5, 2024 at 5:00 p.m. ET AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “
10:00
FinancialContent
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of ...
04 Mar, 2024
18:03
FinancialContent
Plus Therapeutics (NASDAQ:PSTV) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need ...
27 Feb, 2024
AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to di
18 Dec, 2023
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance
12 Dec, 2023
Collaboration to explore novel CSF cancer testing modalities and initial testing panel to be available in Q1 2024 for ReSPECT-LM patientsAUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has partnered with K2bio (Houston, Texas) to implement novel analysis for cere
29 Nov, 2023
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany. 5th Annual Radiopharmaceutic
20 Nov, 2023
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares moved upwards by 74.2% to $1.73 during Monday's regular session. Trading volume ...
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 months, compared to SOC at 4 months Rhenium (186Re) Obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by external
15 Nov, 2023
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here.
13 Nov, 2023
InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, and ABOS.
09 Nov, 2023
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or ...
03 Nov, 2023
AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to rhenium (186Re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM). ODD status is granted by the FDA to
01 Nov, 2023
PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday. The stock continues to gain after reporting third-quarter ...
Gainers Cellectis S.A. (NASDAQ: CLLS) shares jumped 136% to $2.2799. Cellectis reported strategic collaboration and investment ...
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Third Quarter 2023 Results Conference Call. Before we begin, we want to advise you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, […]
Gainers Cellectis S.A. (NASDAQ: CLLS) shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
31 Oct, 2023
Gainers Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for ...
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock. The Company intends to fund any share repurchases with available cash
New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results Completed dosing in Cohort 4 of the Phase 1 ReSPECT-LM dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases, the first of four additional planned cohorts in Part B (Cohorts 4-7);
Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP ...
30 Oct, 2023
Plus Therapeutics (NASDAQ:PSTV) is set to give its latest quarterly earnings report on Tuesday, 2023-10-31. Here's what investors need ...
16 Oct, 2023
Biocept Inc(NASDAQ: BIOC) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. In a ...
29 Sep, 2023
Gainers Bionomics (NASDAQ:BNOX) stock moved upwards by 24.0% to $3.46 during Friday's after-market session. Today's trading volume for ...
18 Sep, 2023
The Dow Jones closed lower by close to 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or ...
11 Sep, 2023
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine ...
Gainers NovaBay Pharmaceuticals (AMEX:NBY) stock rose 109.7% to $1.3 during Monday's pre-market session. The company's market cap ...
08 Sep, 2023
Gainers Biocept (NASDAQ:BIOC) shares increased by 59.4% to $1.34 during Friday's regular session. Trading volume for this security as ...
Biocept Inc(NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide ...
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept’s proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform used in detecting, quantifying, and monitoring tumor status in LM.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement It doesn’t matter if you have $500 or $5 million. Do this now.
Plus Therapeutics Inc(NASDAQ: PSTV) has expanded its supply agreement withBiocept Inc(NASDAQ: BIOC) by acquiring an ...
14 Aug, 2023
Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access. Plus Therapeutics ...
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per ...
11 Aug, 2023
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company ...
Plus Therapeutics Inc(NASDAQ: PSTV) reported data from the ReSPECT-LM study evaluating the company’s lead radiotherapeutic, ...
26 Jul, 2023
Gainers Lixte Biotech Hldgs (NASDAQ:LIXT) stock increased by 13.5% to $4.45 during Wednesday's after-market session. The market value ...
24 Jul, 2023
Gainers Enzo Biochem (NYSE:ENZ) stock moved upwards by 12.5% to $1.53 during Monday's after-market session. The market value of their ...
05 Jul, 2023
Gainers Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 34.7% to $1.68 during Wednesday's pre-market session. The company's market cap ...
30 Jun, 2023
HC Wainwright & Co. has decided to maintain its Buy rating of Plus Therapeutics (NASDAQ:PSTV) and raise its price target from $3.50 ...
29 Jun, 2023
Plus Therapeutics Inc(NASDAQ: PSTV) reported interim updates from the ReSPECT-GBM and ReSPECT-LM studies of rhenium (186Re) ...
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock increased by 657.8% to $29.78 during Thursday's pre-market session. The company's ...
28 Jun, 2023
ICR, a leading strategic communications and advisory firm, is pleased to announce that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, recently appeared on Episode 81 of ICR’s “Welcome to the Arena” podcast.
26 Jun, 2023
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV) was recently a guest on Benzinga’s All-Access. Plus ...
16 Jun, 2023
Friday's session saw 32 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Royalty Pharma ...
13 Jun, 2023
On Tuesday, 32 companies reached new 52-week lows. Key Facts About Today's 52-Week Lows: Vodafone Group ...
18 May, 2023
Norman LaFrance, MD, CMO & Senior VP, and Melissa Moore, PhD, VP of Clinical Research for Plus Therapeutics Inc. (NASDAQ: PSTV) were ...
21 Apr, 2023
According to Benzinga Pro data, during Q1, Plus Therapeutics (NASDAQ:PSTV) posted sales of $506 thousand. Earnings were up 15.08%, but ...
Gainers NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 25.3% to $1.93 during Friday's pre-market session. The company's ...
20 Apr, 2023
Plus Therapeutics (NASDAQ:PSTV) reported its Q1 earnings results on Thursday, April 20, 2023 at 04:05 PM. Here's what investors need to ...
20:10
FinancialContent
Plus Therapeutics (NASDAQ:PSTV) reported its Q1 earnings results on Thursday, April 20, 2023 at 04:05 PM. Here's what investors need to ...
19 Apr, 2023
Plus Therapeutics (NASDAQ:PSTV) is set to give its latest quarterly earnings report on Thursday, 2023-04-20. Here's what investors need ...
23 Feb, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth ...
02 Feb, 2023
Gainers Magenta Therapeutics (NASDAQ:MGTA) stock rose 41.3% to $0.8 during Thursday's after-market session. Trading volume for this ...
19 Oct, 2022

Related Articles